Related Experiment Video
Updated: Aug 6, 2026

Ischemia-reperfusion Model of Acute Kidney Injury and Post Injury Fibrosis in Mice
Published on: August 9, 2013
A1 adenosine receptor knockout mice exhibit increased renal injury following ischemia and reperfusion
H Thomas Lee1, Hua Xu, Samih H Nasr
1Department of Anesthesiology, College of Physicians and Surgeons of Columbia Univ., New York, NY 10032-3784, USA. tl128@columbia.edu
Abstract:
Controversy exists regarding the effect of A1 adenosine receptor (AR) activation in the kidney during ischemia and reperfusion (I/R) injury. We sought to further characterize the role of A1 ARs in modulating renal function after I/R renal injury using both pharmacological and gene deletion approaches in mice. A1 AR knockout mice (A1KO) or their wild-type littermate controls (A1WT) were subjected to 30 min of renal ischemia. Some A1WT mice were subjected to 30 min of renal ischemia with or without pretreatment with 1,3-dipropyl-8-cyclopentylxanthine (DPCPX) or 2-chrolo-cyclopentyladenosine (CCPA), selective A1 AR antagonist and agonist, respectively. Plasma creatinine and renal histology were compared 24 h after renal injury. A1KO mice exhibited significantly higher creatinines and worsened renal histology compared with A1WT controls following renal I/R injury. A1WT mice pretreated with the A1 AR antagonist or agonist demonstrated significantly worsened or improved renal function, respectively, after I/R injury. In addition, A1WT mice pretreated with DPCPX or CCPA showed significantly increased or reduced markers of renal inflammation, respectively (renal myeloperoxidase activity, renal tubular neutrophil infiltration, ICAM-1, TNF-alpha, and IL-1beta mRNA expression), while demonstrating no differences in indicators of apoptosis. In conclusion, we demonstrate that endogenous or exogenous preischemic activation of A1 ARs protects against renal I/R injury in vivo via mechanisms leading to decreased necrosis and inflammation.
Insights
Activating the A1 adenosine receptor (AR) protects the kidney from ischemia-reperfusion (I/R) injury. This study shows A1 AR activation reduces kidney damage and inflammation, highlighting its protective role in renal I/R injury.
Area of Science:
- Nephrology
- Cardiovascular Research
- Immunology
Background:
- The role of A1 adenosine receptor (AR) activation in kidney ischemia-reperfusion (I/R) injury remains controversial.
- Understanding A1 ARs' function is crucial for developing therapeutic strategies against renal injury.
Purpose of the Study:
- To investigate the role of A1 ARs in modulating renal function following I/R injury.
- To elucidate the mechanisms by which A1 ARs exert protective effects in the kidney.
Main Methods:
- Utilized A1 AR knockout (A1KO) and wild-type (A1WT) mice subjected to renal ischemia.
- Administered selective A1 AR antagonist (DPCPX) and agonist (CCPA) to A1WT mice before ischemia.
- Assessed renal function (plasma creatinine) and histology 24 hours post-injury.
Main Results:
- A1KO mice showed significantly worse renal function and histology after I/R injury compared to A1WT controls.
- Pretreatment with A1 AR agonist (CCPA) improved renal function and reduced inflammation markers (MPO, neutrophil infiltration, ICAM-1, TNF-α, IL-1β mRNA).
- Pretreatment with A1 AR antagonist (DPCPX) worsened renal function and increased inflammation markers.
Conclusions:
- Endogenous or exogenous preischemic activation of A1 ARs protects against renal I/R injury.
- A1 AR activation decreases renal necrosis and inflammation, suggesting a therapeutic potential.
- The protective mechanisms involve the modulation of inflammatory pathways without affecting apoptosis.
Related Concept Videos
Adrenergic Receptors: ɑ Subtype
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Acute Kidney Injury II: Pathophysiology

